Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMG+Ven vs VA in MDS-IB2 and Newly Diagnosed Secondary or Elderly AML
NCT07735117Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2028
01
Overview
A Phase 3 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Ruijin Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07735117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735117.